Amubarvimab (BRII-196) is a humanIgG1mAb that bind to non-competing epitopes on thereceptor binding domain (RBD)ofspike protein, with aK_Dof 5.88 nM. Amubarvimab can effectively neutralize SARS-CoV-2 variants^[1][2].

Amubarvimab shows specific activity against wild-type SARS-CoV-2 and no cross-reactivity against other coronaviruses^[1].
Amubarvimab binds to two regions spanning amino acids 453-505 in the receptor-binding motif (RBM) and amino acids residues 403-421 in the core region of RBD^[1].

Amubarvimab (10-50 mg/kg; i.p.) in combination with romlusevimab significantly decreases viral load in the lungs, and reduces lung pathology in a Syrian golden hamster model of SARS-CoV-2 infection^[1].

2509447-07-6

Please store the product under the recommended conditions in the Certificate of Analysis.